| Name | Title | Contact Details |
|---|
TearLab Corporation develops and commercializes lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by quantitatively testing for disease markers in tears at the point-of-care. Headquartered in San Diego, CA, TearLab Corporation`s common shares trade on the NASDAQ Capital Market under the symbol `TEAR` and on the Toronto Stock Exchange under the symbol `TLB`. Dry Eye Disease (DED) is a chronic, progressive disease. Morgan Stanley’s Dry Eye Market Report (2003) estimates that 30 to 60 million Americans suffer from dry eye symptoms. Only 10 million are diagnosed with the disease. Millions more suffer worldwide. The TearLab™ Osmolarity System provides the first quantitative and objective diagnostic technology that allows doctors to effectively manage their dry eye patients. TearLab will allow practitioners to diagnosis DED patients early in the disease process allowing for early intervention. TearLab received the CE Mark for its TearLab Osmolarity System in 2008 and FDA Clearance in 2009. TearLab is currently marketed globally in more than 14 countries including the US.
Cognate BioServices is a Halethorpe, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Surgalign Holdings, Inc. is a global medical technology company committed to the promise of digital health to drive transformation across the surgical landscape. Uniquely aligned and resourced to advance the standard of care, the company is building technologies physicians and other health providers will look to for what is truly possible for their patients. Surgalign is focused on developing solutions that predictably deliver superior clinical and economic outcomes. Surgalign markets products throughout the United States and in approximately 50 countries worldwide through an expanding network of top independent distributors. Surgalign is headquartered in Deerfield, IL, with commercial, innovation and design centers in San Diego, CA, Warsaw and Poznan, Poland and Wurmlingen, Germany.
NanoHybrids specializes in research and commercialization of nanotechnology-based products that enhance diagnosis and therapy for cancer and other diseases through enhanced molecular imaging and profiling. Our molecular imaging nanoparticles enhance contrast in vitro and in vivo across multiple biomedical imaging modalities. We are the leading provider of silica-coated gold nanoparticles optimized for photoacoustic (optoacoustic) imaging. With conjugation services we provide nanoparticles with high specificity for targeted cell receptors and tailored to individual applications. Our nanoparticles improve signal strength and allow real time imaging of functional biology. Interested in learning how we are using nanotechnology to drive advances in the life-sciences? Want learn more about our research, products, or services? Contact us, and let`s talk.
Vital Signs, Inc. is a designer, manufacturer, and marketer of airway management products for the anesthesia, respiratory/critical care, interventional cardiology/radiology and sleep disorder markets. The Company sells its products in over 73 countries